ReviewFrontiers in public health2025
Optimizing HPV vaccine effectiveness: impact of vaccination age and dose schedule on immunogenicity and cervical cancer prevention.
Review in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Role of human papillomavirus (HPV) variants and host genetic susceptibility in cervical carcinogenesis.Archives of microbiology · 2026Review
- Impact of an Educational Intervention Video in HPV Prevention among Tunisian Female Students: A before-and-after Study.Journal of preventive medicine and hygiene · 2025Article
- Cervical Cancer in the Era of HPV: Translating Molecular Mechanisms into Preventive Public Health Action.International journal of molecular sciences · 2025Review
- Burden of 33 malignant tumor groups in 5 socio-demographic index areas and 21 regions from 1990 to 2041.Science progressArticle
- Educational intervention and its effect on medical students' knowledge and readiness for cervical cancer screening and human papillomavirus vaccination.Journal of family & community medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer is the fourth most common cancer among women globally, claiming over 443,000 lives annually, with 98% of these deaths occurring in developing countries. Vaccination against human papillomavirus (HPV) is a preventive strategy. This review investigates the role of age at vaccination and the number of doses in determining vaccine effectiveness. Articles from 2013 to 2023 were retrieved from PubMed, Scopus, SID, and Google Scholar using keywords related to HPV, vaccine, age, and dose. The findings suggest that the highest vaccine effectiveness is observed in younger age groups (ages 9-14: 74-93%) and decreases with age. Studies indicate that while three doses provide optimal protection, a single dose may also confer significant benefits in younger populations. These findings underscore the importance of timely vaccination and adherence to dosing schedules for maximizing vaccine impact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.